AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02767882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
Study NCT02013479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SelenoPRECISE
Description: Produced by Pharma Nord ApS, Vejle, Denmark
Study NCT02013479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Produced by Pharma Nord ApS, Vejle, Denmark
Study NCT04694846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04694846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT02356003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation
Description: Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
Study NCT04459104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic load
Description: Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study NCT00423475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Study NCT00423475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Study NCT00423475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00423475 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00423475 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03595085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter directed fragmentation and thrombolysis
Description: A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
Study NCT03595085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
Study NCT05278728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200,400,600 or 800mg weekly until progression or AEs
Study NCT05278728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
Study NCT03599492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SMART Pill Pre-TIPS
Description: Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
Study NCT03599492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SMART Pill Post TIPS
Description: Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
Study NCT01205386 — intervention group
Intervention type: DEVICE
Intervention: 1. CROSSER System
Description: The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
Study NCT01209130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDT2980S
Description: Intravenous repeating dose
Study NCT01209130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT02592083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin
Study NCT02592083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin
Study NCT02592083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT04097236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative assessment of gastric content volume with bed elevation
Description: Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
Study NCT04694846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT04694846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard treatment
Study NCT04097236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative assessment of gastric content volume without bed elevation
Description: Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
Study NCT00049582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00049582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00049582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04728503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-Minute Mindful Movement Video
Description: 5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
Study NCT04728503 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Educative Materials
Description: 1 page written educative material about the benefits of mindfulness to serve as a control.
Study NCT03050710 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Princess® VOLUME Lidocaine
Description: Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
Study NCT03252912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
Study NCT00963781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Endeavor Stent
Description: The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
Study NCT02341404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-hydroxyflutamide (2-HOF)
Description: Two components are mixed, transferred to a syringe and administered with injection into the prostate
Study NCT00528008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine solution
Description: Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
Study NCT00528008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate
Description: Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
Study NCT02708472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: synchronized Transcranial Magnetic Stimulation (sTMS)
Description: Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes.
Study NCT03507881 — intervention group
Intervention type: DEVICE
Intervention: fusion
Description: Internal fixation
Study NCT02596802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO therapy
Description: Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
Study NCT01211119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No PRF
Description: Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
Study NCT01138397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (split virion, inactivated)
Description: 0.1 mL, Intradermal
Study NCT02680561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI
Study NCT00963781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced duration (6 months) DAPT
Study NCT01489631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naropin
Description: ropivacaine 0,2%, 3x 50 ml during surgery
Study NCT01489631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine
Description: bupivacaine 0,125%
Study NCT01489631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: sufentanil 1mcg/ml
Study NCT01489631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neurontin
Description: gabapentin 600 mg pre-operative 3 dd 300 mg
Study NCT05830149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryoinsufflation
Description: In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
Study NCT02680561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate MDPI
Study NCT01523990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
Study NCT05830149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deroofing
Description: Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
Study NCT00893737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
Description: Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
Study NCT04010149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
Study NCT04010149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS
Description: For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
Study NCT01728064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01728064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 400 mg
Study NCT01728064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 200 mg
Study NCT01827605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZEVALIN
Description: Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
Study NCT01827605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc
Study NCT02282579 — intervention group
Intervention type: DRUG
Intervention: Pazopanib
Description: Non interventional study
Study NCT04546438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry®
Description: MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions).
Study NCT02680561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol MDPI
Study NCT02680561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol MDPI
Study NCT02680561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Study NCT02680561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol
Study NCT01736709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012-2013 trivalent seasonal influenza vaccine
Description: trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
Study NCT00255008 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
Study NCT00255008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
Study NCT00255008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
Study NCT04310969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiBoFlo Thermoflo
Description: Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
Study NCT04310969 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: forceful expression of the meibomian glands
Description: Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
Study NCT04310969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: forceful expression of the meibomian glands
Description: Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
Study NCT04310969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow
Description: LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
Study NCT03343652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg IV infusion on day 1,14 up to 3 cycles
Study NCT03343652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: 90 mg/kg IV infusion on day 1 up to 3 cycles
Study NCT02734654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
Study NCT02337959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
Study NCT03058432 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Study NCT03058432 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Study NCT04557020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
Study NCT04557020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
Study NCT04557020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles